Avantor Investor Conference Presentation Deck
Robust fundamentals drive double-digit
long-term end market growth
STRONG PIPELINE OF
BIOLOGIC THERAPIES
mAbs: >30 new
therapies approved in
last 2 years, ~2,500
active clinical projects
New modalities:
>2,000 active clinical
projects
BIOLOGICS
>10%
Long-term
market growth
CAGR:
2023E TOTAL MARKET REVENUE FOR BIOLOGICS
MONOCLONAL
ANTIBODIES
>10%
53%
GLP-1
>20%
Source: Evaluate Pharma data as of November 2023. CAGRS represent estimated revenue growth from 2018 to 2028. mAbs
include traditional mAbs and recombinant antibodies. GLP-1 therapies include dual agonist therapies. Other protein therapies
include insulin. Other includes nucleic acids, vaccines, etc. 1. CAGR inflated due to COVID-19 vaccine forecast uncertainty.
8%
OTHER PROTEIN
THERAPIES
>2%
19%
CELL & GENE
THERAPIES
>30%
3%
17%
OTHER
(e.g., mRNA)
>12%¹
Navantor™ 15View entire presentation